NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hrain Biotechnology Co., Ltd.

Hrain Biotechnology Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttps://dashengbio.com/

Last Round

Series C

Apr 26, 2021

Est. Valuation

$657M

Total Funding Raised

$118.99M

Company Overview

Hrain Biotechnology Co., Ltd. is a biotechnology company that specializes in the research, development, and manufacturing of breakthrough immune cell therapies, including CAR-T and CAR-NK products, for the treatment of hematologic malignancies and solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapycell therapyimmunotherapyCAR-NK cell therapyTCR-T cell therapybiopharmaceuticalGMP manufacturingprecision medicinehematologic malignanciesoncologyliving drugscancer immunotherapycell manufacturingbiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hrain Biotechnology Co., Ltd. Comparables

Compare Hrain Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.

Hrain Biotechnology Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Juventas Cell Therapy Ltd.
87%
PersonGen BioTherapeutics
87%
JW Therapeutics
86%

Hrain Biotechnology Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 26, 2021
Series B ExtensionSep 8, 2020
Series BSep 30, 2019
Series AApr 1, 2018

Hrain Biotechnology Co., Ltd. Investors

Notable investors and investment history

Hrain Biotechnology Co., Ltd. investors
InvestorRounds
Xinyi CapitalSeries B Extension
Shenzhen Capital GroupSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 30, 2019

    $28M round led by Shenzhen Capital Group

Hrain Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hrain Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hrain Biotechnology Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range23
Year Founded2015
Last FundingApr 26, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.